Duncan Park Holdings Corporation Announces Results of Annual and Special Meeting
Toronto, Ontario - (Newsfile Corp. – July 2, 2020) - Duncan Park Holdings Corporation (OTC Pink: DCNPF) (the “Company” or “Duncan Park”) today announced the results of its 2020 Annual and Special Meeting of shareholders held on Tuesday, June 30, 2020 in Toronto, Canada.
At the meeting shareholders approved all the resolutions detailed in the management information circular of the Company dated May 29, 2020 (the “Circular”), namely:
- Fixing the size of the Board of Directors of the Company at five.
- Electing all the management nominees to the Board of Directors of the Company;
- Re-appointing Clearhouse LLP as auditor of the Company for the ensuing year and authorizing the directors to determine the auditor’s compensation;
- Confirming and ratifying the Company’s stock option plan;
- Approving a special resolution authorizing a change of name of the Company to "Psyched Wellness Ltd." or such other name as the Board of Directors of the Company may choose, acting in the best interests of the Company; and
- Approving a special resolution authorizing the Board of Directors of the Company to fix from time to time the number of directors to be elected at annual general meetings of the shareholders of the Company within the minimum and maximum number of directors permitted by the Company's articles.
A total of 42,379,816 common shares of the Company were voted at the meeting, representing approximately 52.68% of the issued and outstanding common shares of the Company and all matters received the approval of more than 99% of the shares voted thereon.
The Company will make arrangements to complete the name change and will make a further announcement when the effective date of the name change is known.
Neither the Canadian Securities Exchange nor its Regulation Services Provider have reviewed or accept responsibility for the adequacy or accuracy of this release.
About Psyched Wellness Ltd.:
Psyched Wellness Ltd. is a Canadian-based health supplements company dedicated to the distribution of mushroom-derived products and associated consumer packaged goods. The Company’s objective is to create premium mushroom-derived products that have the potential to become a leading North American brand in the emerging functional food category. The Company is in the process of developing a line of Amanita muscaria-derived water-based extracts, teas and capsules designed to help with three health objectives: promote stress relief, relaxation and assist with restful sleeping.
Cautionary Statement Regarding Forward Looking Information
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. These statements relate to future events or future performance. The use of any of the words “could”, “intend”, “expect”, “believe”, “will”, “projected”, “estimated” and similar expressions and statements relating to matters that are not historical facts are intended to identify forward-looking information and are based on the Company’s current belief or assumptions as to the outcome and timing of such future events. The forward-looking information and forward- looking statements contained herein include, but are not limited to, statements regarding: the ability of the Company to develop Amanita Muscaria-derived products; the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and (ii) the uses and potential benefits of Amanita Muscaria.
Forward-looking information in this news release are based on certain assumptions and expected future events, namely: the Company’s ability to continue as a going concern; the Company’s ability to continue to develop its mushroom-derived products and associated consumer packaged goods; continued approval of the Company’s activities by the relevant governmental and/or regulatory authorities; and the continued growth of the Company.
These statements involve known and unknown risks, uncertainties and other factors, which may cause actual results, performance or achievements to differ materially from those expressed or implied by such statements, including but not limited to: the potential inability of the Company to continue as a going concern; risks associated with potential governmental and/or regulatory action with respect to the Company’s operations; competition within the psychedelics market; risks with respect to the safety of Amanita Muscaria consumption and the safety and purity of any extracts thereof; and the risk that there is no potential benefit of Amanita Muscaria consumption.
Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated.
Forward-looking statements contained in this news release are expressly qualified by this cautionary statement and reflect the Company’s expectations as of the date hereof and are subject to change thereafter. The Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, estimates or opinions, future events or results or otherwise or to explain any material difference between subsequent actual events and such forward-looking information, except as required by applicable law.